Lilly's New Year Resolution: Make New Launches Into Blockbusters
Executive Summary
Lilly laid out its 2019 financial forecast and commercial and R&D goals during an investor event in New York. While there were no big surprises, the company updated investors on important catalysts in diabetes, immunology, oncology and pain.
You may also be interested in...
Lilly Is Growing Its Next Crop Of Blockbusters
The pharma is digging deeper with early- and mid-stage R&D in age-related neurodegeneration, diabetes/obesity and other priority areas.
Shaw Leaves Lilly To Helm Gilead’s Kite
After heading up Lilly Bio-Medicines for two-and-a-half years, Shaw will take over Gilead’s gene therapy subsidiary. At Lilly, she oversaw the approvals of Olumiant and Emgality and helped grow Taltz.
Lilly’s Cyramza Shows Promise In First-Line NSCLC – But Not Much Room To Grow
Studied with Tarceva, Cyramza showed an ability to improve PFS in patients with EGFR-mutant tumors. But how will a two-company combo fare against Tagrisso monotherapy?